BlackHill Fund

The Dementia Discovery Fund (DDF) is a £250m specialist venture capital fund that invests in, and creates, new biotech companies to deliver high impact therapeutics for age-related dementias. By making meaningful, sustained, and actively managed investments we will enable the development of therapeutics addressing one of the largest global unmet medical needs, thus generating significant returns for our investors. The Dementia Discovery Fund will succeed in this challenging but rewarding space by taking a venture investing approach combined with deep domain expertise and active management. The DDF will invest to rapidly progress diverse approaches into clinical development for all forms of dementia including Alzheimer’s Disease (AD), Parkinson’s Disease Dementia (PDD), Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s Disease (HD). The DDF team will leverage learnings from its dementia-focused team and portfolio. By seeking and receiving advice from our sophisticated investor base, our Scientific Advisory Board (SAB), and our network of academic thought leaders, we will make investments deeply informed by rigorous scientific insight and years of experience developing therapeutics. In addition, our portfolio companies have access to a broad group of potential partners and acquirers, including our SAB, portfolio company syndicate partners, and the industry and venture network of our experienced team. We seek companies led by bold entrepreneurs, across the full spectrum of company and asset stage opportunities. Where we do not see others leading the way to create companies informed by cutting edge science that can make a difference to dementia patients, we will build those companies ourselves, assisted by our bench of experienced entrepreneurs and company creators. History Established in 2015, the Dementia Discovery Fund (DDF) saw its final close at £250 million in 2018 making the DDF the world’s largest venture capital fund focused on discovering and developing novel disease-modifying therapeutics for all forms of dementia. Seven leading pharmaceutical companies – Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda – along with AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, the UK’s Department of Health and Social Care, and the charity Alzheimer’s Research UK (among others) have invested in the DDF. Advised by SV Health Investors (SV), a leading life sciences venture capital and growth equity firm, the investment and strategic support the DDF can provide is unrivalled. SV has been investing in biotech companies for over 25 years and brings a proven track record of identifying early-stage research opportunities and supporting their development into novel medicines. The DDF has a mandate to interrogate novel hypotheses and expand the breadth of targets and mechanisms in development for dementia therapies over the life of the fund. This mandate enables the DDF to invest in truly novel, early stage projects starting from target identification onwards to explore novel biological insights for translation into disease modifying drugs. The Impact of Dementia The challenge posed by dementia is enormous. As the average age of the population grows, dementia is one of the biggest global health threats we face, and the challenge is growing. Worldwide, around 50 million people are affected by dementia and every year there are nearly 10 million new cases. According to the World Health Organization, the total number of people with dementia is projected to reach 82 million in 2030 and 152 million in 2050. These demographics include not only AD, but other dementias such as PDD, FTD, ALS and HD. Dementia is a cruel disease that robs people of their abilities, personality and dignity, creating a significant burden for families and society. Contributing to this burden is the lack of effective treatments for people with dementia. Finding ways to treat this condition is critical but has, so far, proven extremely difficult due to the complexity of the origin and manifestation. As a result, there are currently no existing therapies that have a meaningful impact on the downward progression of dementia symptoms or the disease. However, the historic difficulty of developing treatments for dementia is not a reason to give up, but a reason to try harder. Scientists are learning from adjacent fields, such as the recent advances in immuno-oncology, and innovative research is opening-up new opportunities beyond the well explored scientific hypotheses.

After years of building companies and raising nine figures of venture capital, we recognized a gap in the consumer funding landscape and came together to bridge it. The Family Fund & Founder Community (“The Family Fund”, “F3C”) is purpose built to be a different breed of VC that gives founder-centric new meaning through hands-on support from proven operators, integration into the highest value consumer community, and unparalleled immersive experiences that drive meaningful bonds. We invest in the future of the consumer ecosystem – partnering with innovators across products and technologies striving to continuously upgrade the human experience Our focus Product: The next wave of iconic brands in Health & Wellness, Beauty & Personal Care, Food & Beverage, Pet, Home and beyond Technology: Breakthrough customer-facing platforms that enable users to lead more empowered lives, as well as business-facing solutions that act as engines for commerce to help brands grow and better serve their end consumers Early stage investing: Primary focus around Series A stage, while selectively backing high conviction earlier and growthier stage businesses that we find compelling and differentiated Our LP family It is important to us that in addition to our team our founders also have access to a deep support network of industry leaders. This includes our curated LP community comprising of 100+ top consumer founders and operators eager to lend their expertise to the next generation of trailblazers.

Overton Venture Capital is a woman led fund that invests in seed and early stage, revenue generating companies whose entrepreneurs break the world’s confines and reimagine it with transformational solutions for next-generation businesses. THE OPPORTUNITY: Technology continues to power rapid digital transformation, so much so that consumers are shifting their behaviors and preferences in how they discover, shop and buy in a next-gen commerce world. We invest in companies that capitalize on this transformation and seek to ultimately transform their sectors. COMPANIES WITH OUR SHARED DNA:Founders and Teams We identify and invest in outstanding teams that are on the cusp of disrupting legacy industries. We are inspired by the people who create innovative products that answer consumer needs. Diversity We believe that teams comprised of diverse backgrounds and different perspectives generate powerful solutions that shape tomorrow’s world. We are committed to backing companies with diverse leadership and balanced teams. Integrity This is a partnership after all. We only work with teams of the highest integrity and those who are unwavering in their commitment to running their businesses. We, in turn, will always be open, honest, and transparent with our portfolio companies and partners. Performance We are motivated to partner with companies that have generated rapid growth through fiscal prowess, product differentiation, and competitive advantage. We look for companies that develop scalable, differentiated and defensible products that outperform the market. HOW OUR TEAMS WORK TOGETHER: As founders and operators ourselves, we seek opportunities where we can create value and a sustainable advantage for our companies. Our team plays an active, hands-on role with each portfolio company to help fill the gaps where they need it most to amplify growth.

For the last decade, Bullpen has funded 100+ companies. We do one thing, and we do it well: Post-seed financing for people and companies that have found that special product-market fit but are overlooked for no good reason. Together, we will build the next generation of great businesses.

Fifth Star Funds is a venture philanthropy fund seeking to address the funding epidemic in America where only 1% of venture capital is awarded to Black founders. We accomplish this by investing in Black tech founders in Chicago at the early stage “Friends & Family” round. We believe the funding gap at this stage is the most critical to address, as centuries of inequity have prevented these potential entrepreneurs from having the initial capital to start their businesses. Any individual, corporation, or foundation can contribute to the fund as a tax-deductible donation, and 100% of all returns from successful investments are reinvested into the fund to support future generations of underrepresented founders. We are partnered with leaders in the industry such as 1871, Winston & Strawn, Tides.org, and many more. The Chicago flag features four stars that represent pivotal events in our city’s history; we contend that the Fifth Star belongs to underrepresented founders and the extraordinary impact they will have on our city’s future.

Manulife Financial Corporation is a Toronto-headquartered financial services institution founded in 1887, operating across Asia, Canada, and the United States. The company delivers life and health insurance, wealth management, investment management, retirement planning, group benefits, and retail banking services through subsidiaries including John Hancock in the United States and Manulife Bank. With more than 135 years of operation, Manulife serves millions of individual, family, and institutional clients across its three core geographic markets. The company's business model spans the full spectrum of financial services distribution, from individual insurance policies and retirement accounts to employer-sponsored group benefits and investment management mandates. Product lines include traditional life and health insurance, workplace benefits administration, retirement planning services, discretionary investment management, and commercial and retail banking solutions. This diversified revenue base allows Manulife to maintain positions across multiple customer segments and risk profiles within the financial services value chain. Manulife's technology infrastructure incorporates Salesforce for customer relationship management, Power BI and Tableau for business intelligence and analytics, and Excel for financial modeling and analysis. The company positions digital innovation as a core operational priority alongside its traditional financial strength, though specific digital product offerings or platform investments are not publicly detailed. Roy Gori serves as Chief Executive Officer.